Track topics on Twitter Track topics that are important to you
ELOXATIN® (oxaliplatin injection)200 mg/40mL vial
GMID PACK CODE: 315927
QUANTITY: 240 vials
PROCESS ORDER No: **********
Caution: For manufacturing, processing or repacking.
Store at 25°C (77°F); excursions permitted to 15 - 30°C (59 - 86°F).
Do not freeze and protect from light
Manufactured by:Aventis Pharma Ltd. Rainham Rd South, Dagenham, Essex, RM10 7XS, UK
Made in UK
Aventis Pharma Ltd.
Primary objective: To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin+5-FU/LV Secondary objective:...
This is a Phase II, open-label, non-randomized study in patients with advanced non-squamous NSCLC. Each cycle will be 21 days. Patients will be evaluated every 2 cycles (~6 weeks) for ...
In patients with pleural or peritoneal mesothelioma, what is the response rate to combined Oxaliplatin (ELOXATIN®) and Gemcitabine chemotherapy?
XELOX (Capecitabine and Oxaliplatin) is an effective and convenient regimen for patients with metastatic colorectal cancer. Chronomodulated therapy may reduce toxicity. Patients will be ra...
These are Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory or relapsing pediatric solid tumors.
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...